Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme

Journal of Crohn's & colitis

Volumn 11, Issue 6, 2017, Pages 690-696

  Razanskaite, Violeta ^a   Bettey, Marion ^a   Downey, Louise ^a   Wright, Julia ^a   Callaghan, James ^a   Rush, Miles ^a   Whiteoak, Simon ^a   Ker, Sarah ^a   Perry, Kim ^a   Underhill, Caron ^a   Efrem, Eren ^a   Ahmed, Iftikar ^a   Cummings, Fraser ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

biosimilar switching; biosimilars; gain share; Inflammatory bowel disease; Infliximab

Indexed keywords

ANTIBODY; BIOSIMILAR AGENT; C REACTIVE PROTEIN; CT-P13; GASTROINTESTINAL AGENT; HEMOGLOBIN; INFLIXIMAB; MONOCLONAL ANTIBODY; SERUM ALBUMIN;

ADOLESCENT; ADULT; AGED; BLOOD; DRUG COST; DRUG EFFECTS; DRUG SUBSTITUTION; ECONOMICS; FEMALE; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PATIENT-REPORTED OUTCOME; PLATELET COUNT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; C-REACTIVE PROTEIN; DRUG COSTS; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL AGENTS; HEMOGLOBINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PLATELET COUNT; SERUM ALBUMIN; YOUNG ADULT;

EID: 85019131687     PISSN: None     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw216     Document Type: Article

References (0)